Stryker Corporation
Stryker Reports 2024 Operating Results and 2025 Outlook
Summary
Stryker Corporation announced its fourth quarter and full-year 2024 operating results on January 28, 2025. Net sales increased by 10.7% to $6.4 billion for the quarter and 10.2% to $22.6 billion for the full year. Despite a decrease in reported earnings due to goodwill impairments and other charges, adjusted earnings per share increased by 15.9% to $4.01 for the quarter and 15.0% to $12.19 for the full year. Stryker expects organic net sales growth of 8.0% to 9.0% and adjusted net earnings per diluted share of $13.45 to $13.70 for 2025. The guidance reflects expected modest favorable impact of price on sales and unfavorable impacts from foreign exchange rates and other factors.
Profitelligence Alerts
Get alerts for SYK
Be first to know when Stryker Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Stryker Corporation
Stryker Corporation is a prominent player in the medical technology industry, known for its innovative solutions across healthcare sectors such as orthopedics, medical and surgical, and neurotechnology and spine. The company's purpose is to enhance patient care through its wide array of products, including surgical equipment and advanced medical devices. Stryker plays a critical role in the healthcare market by providing essential tools and technologies that assist in improving surgical precision and patient recovery processes. With a continuous focus on research and development, Stryker Corporation remains at the forefront of medical advancements, directly impacting hospitals, surgical centers, and healthcare providers globally. The company's extensive distribution network and partnerships with medical professionals ensure that its technologies contribute to improving health outcomes across diverse geographical regions.
Official SEC Documents
Advertisement